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To determine whether acute kidney injury results in later
long-term decline in kidney function we measured changes
in kidney function over a 3-year period in adults undergoing
coronary angiography who had serum creatinine
measurements as part of their clinical care. Acute kidney
injury was categorized by the magnitude of increase in serum
creatinine (mild (50–99% or X0.3mg/dl) and moderate or
severe (X100%)) within 7 days of coronary angiography.
Compared to patients without acute kidney injury, the
adjusted odds of a sustained decline in kidney function at
3 months following angiography increased more than 4-fold
for patients with mild to more than 17-fold for those with
moderate or severe acute kidney injury. Among those with
an estimated glomerular filtration rate after angiography less
than 90ml/min per 1.73m2, the subsequent adjusted mean
rate of decline in estimated glomerular filtration rate during
long-term follow-up (all normalized to 1.73m2 per year) was
0.2ml/min in patients without acute kidney injury, 0.8ml/min
following mild injury, and 2.8ml/min following moderate to
severe acute kidney injury. Thus, acute kidney injury
following coronary angiography is associated with a
sustained loss and a larger rate of future decline in
kidney function.
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Acute kidney injury (AKI) following coronary angiography is
often transient, with improvement in kidney function
observed within days to weeks.1–3 Although severe AKI that
requires dialysis is a rare event in this setting,4,5 even AKI of
lesser severity has been consistently associated with adverse
outcomes including death.6,7 Patients with preexisting
chronic kidney disease (CKD) constitute a high-risk group
for AKI in the setting of radiocontrast administration.2
Furthermore, CKD itself is associated with graded increases
in risk of mortality with incremental reductions in glomer-
ular filtration rate (GFR).8–10 These observations suggest that
the long-term effects of AKI on the development and
progression of CKD are important to understand.
The long-term trajectory of kidney function following an
episode of AKI remains unclear. The majority of what is
currently known relates to the risk of developing end-stage
renal disease (ESRD) requiring dialysis among survivors of
severe AKI.11–13 The effects of lesser degrees of AKI have not
been characterized, nor have the long-term effects of AKI on
kidney function based on the rate of decline in estimated
GFR (eGFR) after hospital discharge. Furthermore, the
effects of AKI on serial post-procedure measurements of
kidney function have not been examined following coronary
angiography specifically, an event which is particularly
relevant given the high cardiovascular risk and use of this
procedure in patients with or at risk for CKD. Identification
of patients at high risk for progressive loss of kidney function
after these procedures would provide important prognostic
information to guide subsequent patient care.
The purpose of this study was to examine the association
between AKI and long-term changes in kidney function
following coronary angiography. We hypothesized that a
graded association would exist between the severity of an AKI
episode and loss of kidney function at 3 months after
angiography. We also hypothesized that AKI would be an
independent predictor of the subsequent rate of decline in
GFR beyond 3 months following coronary angiography.
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RESULTS
Cohort formation and characteristics
We identified 19,022 Alberta residents 18 years of age or older
undergoing coronary angiography withX1 outpatient serum
creatinine measurement performed in both the pre- and
greater than 3-month post-angiography time periods. We
excluded 327 patients receiving renal replacement therapy
before study entry, and 616 patients who underwent coronary
artery bypass surgery within 7 days following angiography.
Of the remainder, 11,249 (62.2%) had a serum creatinine
measurement within 7 days following coronary angiography,
and were included in the final cohort (Figure 1).
The mean age of the cohort was 63.6 years, 69.6% were
men, and the mean eGFR before coronary angiography was
73.8 ml/min per 1.73 m2. A total of 853 participants (7.6%)
developed AKI following coronary angiography; 716 (6.4%)
with mild AKI (increase in serum creatinine 50–99% or by
X0.3 mg/dl) and 137 (1.2%) with moderate or severe AKI
(increase in serum creatinine X100%). Patients who
developed AKI were older, more likely to be women, with
lower pre-angiography eGFR, proteinuria, and several
comorbidities including diabetes mellitus, hypertension,
and heart failure (Table 1).
Median follow-up from the date of coronary angiography
was 2.5 years (interquartile range (IQR) 2.2, 2.8 years). The
median number of serum creatinine measurements obtained
between 7 days and 3 months after angiography was 6 (IQR
4, 9), whereas the median number of outpatient serum
creatinine measurements obtained 43 months after angio-
graphy was 3 (IQR 2, 4), with a median interval between
measurements of 7 months (IQR 1, 11 months). During
follow-up beyond 3 months after coronary angiography, 638
participants (5.7%) died, whereas 46 (0.4%) initiated chronic
renal replacement therapy.
Table 1 | Characteristics of patients undergoing coronary angiography, according to AKI status
No AKI
(n=10,396)
Mild AKI
(n=716)
Moderate or severe
AKI (n=137) P-valuea
Age, years, mean (s.d.) 63.3 (12.2) 68.3 (11.8) 66.8 (12.0) o0.0001
Sex, male, no. (%) 7263 (69.9) 490 (68.4) 79 (57.7) 0.007
Pre-angiography eGFR, ml/min per 1.73m2, mean (s.d.) 74.0 (19.8) 62.4 (24.3) 61.8 (26.2) o0.0001
Pre-angiography eGFR, categories, no. (%)
X90ml/min per 1.73m2 1897 (18.2) 84 (11.7) 16 (11.7) o0.001
60–89ml/min per 1.73m2 6195 (59.6) 280 (39.1) 49 (35.8)
30–59ml/min per 1.73m2 2196 (21.1) 315 (44.0) 59 (43.1)
o30ml/min per 1.73m2 108 (1.0) 37 (5.2) 13 (9.5)
Proteinuria, no. (%)
Absent 6779 (65.2) 424 (59.2) 71 (51.8) o0.001
Microalbuminuria 1225 (11.8) 161 (22.5) 50 (36.5)
Proteinuria 40 (3.8) 11 (1.5) 1 (0.7)
Unmeasured 2352 (22.6) 120 (16.8) 15 (10.9)
Comorbidities, no. (%)
Diabetes mellitus 2730 (26.3) 265 (37.0) 62 (45.2) o0.001
Hypertension 7024 (67.6) 537 (75.0) 93 (67.9) o0.001
Hyperlipidemia 8098 (77.9) 538 (75.1) 90 (65.7) 0.001
Heart failure 1450 (13.9) 224 (31.3) 60 (43.8) o0.001
Cerebrovascular disease 751 (7.2) 83 (11.2) 25 (18.2) o0.001
Peripheral vascular disease 786 (7.6) 84 (11.7) 20 (14.6) o0.001
Chronic pulmonary disease 1709 (16.4) 190 (26.5) 29 (21.1) o0.001
Liver disease 141 (1.4) 14 (2.0) 5 (3.6) 0.014
Malignancy 451 (4.3) 41 (5.7) 8 (5.8) 0.16
Current smoker 3030 (29.1) 166 (23.2) 25 (18.2) o0.001
Procedures following diagnostic angiogram, no. (%)
Percutaneous coronary intervention 5356 (51.5) 329 (45.9) 50 (36.5) o0.001
Coronary artery bypass surgery 1335 (12.8) 112 (15.6) 21 (15.3) 0.072
Abbreviations: AKI, acute kidney injury; s.d., standard deviation.
aANOVA or w2-test.
Alberta residents age 18 years old receiving coronary
angiography from 1 Jan 2004 – 31 Dec 2006 with
creatinine measurements before and >3 months
after angiogram (n = 19,022)
Pre-existing ESRD (n =327)Excluded
Excluded CABG surgery within 7 days
after angiogram (n =616)
No serum creatinine measurements
within 7 days after angiogram
(n =6830)
Study cohort
(n =11,249)
Excluded
Figure 1 |Cohort formation.
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Loss of kidney function at 3 months following coronary
angiography
The proportion of patients with a sustained loss of kidney
function (serum creatinine concentration 450% or 0.3 mg/dl
above pre-angiography concentration 43 months following
the procedure) increased with greater severity of AKI,
occurring in 5.9% of patients without AKI, 28.2% of patients
with mild AKI, and 59.1% among patients with moderate or
severe AKI (Table 2). In the final model adjusted for age, sex,
pre-angiography eGFR, proteinuria, comorbidities, and
revascularization procedures, compared with patients with-
out AKI, the odds of a decline in kidney function by
3 months increased more than 4-fold for subjects with mild
AKI Stage (odds ratio (OR) 4.74, 95% confidence interval
(CI) 3.92–5.74), and more than 17-fold for those with
moderate or severe AKI (OR 17.31, 95% CI 12.03–24.90).
Long-term decline in kidney function following coronary
angiography
Among the 10,418 (92.6%) patients with a post-angiography
eGFR o90 ml/min per 1.73 m2 more than 3 months
following angiography, those who had developed AKI had
lower eGFR at 3 months, as well as further decline in eGFR
during subsequent long-term follow-up (Figure 2). The
unadjusted mean annual rate of decline in eGFR during long-
term follow-up was 0.1 (95% CI 0.1 to 0.2) ml/min per
1.73 m2 per year among patients without AKI, 1.0 (95% CI
0.4–1.5) ml/min per 1.73 m2 per year among patients with
mild AKI, and 3.1 (95% CI 2.0–4.2) ml/min per 1.73 m2 per
year among patients with moderate or severe AKI. After
adjustment for age, sex, proteinuria, and comorbidities, the
adjusted rate of decline in eGFR was 0.2 (95% CI 0.4 to 0.8)
ml/min per 1.73 m2 per year in patients without AKI, 0.8
(95% CI 0.1–1.6) ml/min per 1.73 m2 per year in those who
had developed mild AKI, and 2.8 (95% CI 1.7–4.1) ml/min
per 1.73 m2 per year in patients who had experienced
moderate to severe AKI (P-trend o0.001). The odds of
rapid progression of kidney disease during the long-term
follow-up period also increased in a graded manner with
increasing severity of AKI (Table 3). The test for interaction
between AKI and post-angiogram eGFR was nonsignificant
(P-interaction 0.24) suggesting that AKI was associated with
similar risks of subsequent rapid progression of kidney
disease regardless of the eGFR at the start of long-term
follow-up.
Comparison of pre- and post-angiography rates of
decline in kidney function
There were 5,478 (59.2%) patients who also had estimates of
GFR available spanning 41 year before angiography with
which to estimate the pre-angiography rate of decline in
kidney function. The annual rate of decline in eGFR was
similar for the pre- and the post-angiography time periods
for patients without AKI or with mild AKI. For patients
who experienced moderate or severe AKI, there was a
statistically significant increase in the rate of decline in kidney
function following the episode of AKI by 1.8 (95% CI
0.6–3.0) ml/min per 1.73 m2 per year, compared with the
pre-angiography rate.
Sensitivity analyses
Sensitivity analyses were conducted to explore the impact of
the number and frequency of serum creatinine measurements
on results. For the analysis of kidney function at 3 months,
we restricted the cohort to patients who had X2 creatinine
measurements obtained between 7 days and 3 months
Table 2 | Sustained loss of kidney function at 3 months following coronary angiography
No AKI Mild AKI Moderate or severe AKI
No. of patients 10,396 716 137
No. serum creatinine measurements per patient, median (IQR) 6 (3, 9) 8 (5, 14) 7 (4, 17)
Decline in kidney functiona
No. (%) 613 (5.9) 202 (28.2) 81 (59.1)
Crude odds ratio (95% CI) 1 (reference) 6.30 (5.25–7.56) 23.20 (16.34–32.94)
Adjusted odds ratio (95% CI)b 1 (reference) 4.74 (3.92–5.74) 17.31 (12.03–24.90)
Abbreviations: AKI, acute kidney injury; CI, confidence interval.
aLoss of kidney function=serum creatinine450% or 0.3mg/dl above pre-angiography concentration on all measurements obtained 7 days to 3 months following angiogram.
bFinal model adjusted for age, sex, pre-angiography eGFR, proteinuria, comorbidities (diabetes mellitus, hypertension, heart failure, cerebrovascular disease, chronic
pulmonary disease), revascularization following coronary angiogram (percutaneous coronary intervention or coronary artery bypass surgery).
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Figure 2 |Kidney function following coronary angiography
among patients with post-angiography estimated glomerular
filtration rate (eGFR) o90ml/min per 1.73m2, according to
acute kidney injury status.
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following angiography, which produced similar findings
to our primary analysis. For the analysis of long-term
progression of kidney function beyond 3 months following
angiography, we stratified the cohort according to the
number of serum creatinine measurements during the
follow-up period (p 2, 3, or X4 measurements). Although
the subsequent rate of decline in eGFR increased with greater
number of serum creatinine measurements across all
categories of AKI, the relative increases in rate of decline in
eGFR, and odds of rapid progression with mild and moderate
or severe AKI were comparable across all strata to those
observed in the primary analyses.
DISCUSSION
In this large cohort undergoing coronary angiography, a loss
of kidney function at 3 months following coronary
angiography was common after AKI. Among patients with
an eGFRo90 ml/min per 1.73 m2 following angiography, the
long-term risk of further progressive loss of kidney function
also increased with greater severity of AKI. Furthermore,
patients with moderate or severe AKI experienced accelera-
tion in the rate of eGFR decline following an episode of AKI
compared with their pre-angiography rate of progression.
These results show that patients who develop AKI following
coronary angiography are at increased risk for progressive
long-term loss of kidney function following angiography.
Although the short-term adverse effects of AKI during
hospitalization are well recognized,7,14,15 the long-term
effects of AKI on renal outcomes have been unclear because
comparisons to patients without AKI have been lacking, the
confounding effects of preexisting CKD have not been
controlled for, or identification of progression of kidney
disease has been based solely on receipt of treatment for
ESRD.16,17 Elderly patients hospitalized with diagnosis codes
for AKI superimposed on CKD11 as well as patients with
increases in creatinine following hospitalization with myo-
cardial infarction have been shown to be at increased risk for
enrollment in ESRD programs in the United States.18 Severe
AKI leading to dialysis during hospitalization has recently
been shown to be associated with an increased risk for
chronic renal replacement therapy in later life,12,13 whereas
patients with diagnosis codes for acute tubular necrosis or
dialysis-requiring AKI have also been reported to be at risk
for earlier identification of stage 4 or 5 CKD.19,20
This analysis expands upon the findings of previous
studies by identifying both AKI and subsequent changes in
kidney function using serial measurements of serum
creatinine and eGFR. This is a significant advantage given
the limitations in sensitivity and specificity when using
administrative codes to define AKI and CKD in isolation or
combination.21–23 Furthermore, the use of pre- and post-
angiography estimates of GFR allowed for the confounding
effects of preexisting CKD (and its severity) to be accounted
for in these analyses.16
A number of mechanisms may explain the associations
between AKI and progressive loss of kidney dysfunction
following coronary angiography. First, the association may be
due to numerous comorbidities (that is, hypertension,
diabetes mellitus, proteinuria, or later stages of CKD) in
patients who develop AKI. However, the magnitude of the
associations that remained after statistical adjustment
suggests that confounding by these characteristics is unlikely
to explain our findings. Second, patients who develop
AKI may be more likely to have a serum creatinine
measurement obtained during follow-up, thus introducing
potential for ascertainment bias. However, we observed
similar results when analyses were stratified by the number
of serum creatinine measurements performed during
Table 3 | Long-term changes in kidney function beyond 3 months following coronary angiography among patients with
post-angiography eGFR o90ml/min per 1.73m2 (n=10,418), according to AKI status
No AKI Mild AKI Moderate or severe AKI
No. of patients 9539 742 137
eGFR 3 months post-angiography, ml/min per 1.73m2 (95% CI) 66.0 (65.7–66.3) 53.4 (50.1–52.7) 51.5 (48.8–54.1)
Follow-up duration, months, median (IQR) 21.8 (13.0, 30.8) 20.4 (12.8, 30.1) 22.5 (13.4, 30.4)
No. serum creatinine measurements per patient, median (IQR) 3 (1, 5) 4 (2, 8) 4 (2, 10)
Rate of decline in eGFR (ml/min per 1.73m2/year)
Crude mean (95% CI) 0.1 (0.1–0.2) 1.0 (0.4–1.5) 3.1 (2.0–4.2)
Adjusted mean (95% CI)a 0.2 (0.4–0.8) 0.8 (0.1–1.6) 2.8 (1.7–4.1)
Rapid progression of kidney disease
Decline in eGFR 44ml/min per 1.73m2 per year, no. (%) 333 (3.4) 58 (7.8) 22 (16.0)
Initiated chronic renal replacement therapy, no (%) 21 (0.2) 18 (2.4) 8 (5.8)
Composite outcomeb
Crude odds ratio (95% CI) 1 (reference) 2.81 (2.15–3.67) 6.52 (4.22–10.07)
Adjusted odds ratio (95% CI)c 1 (reference) 1.60 (1.19–2.14) 3.12 (1.95–4.99)
Abbreviations: AKI, acute kidney injury; eGFR, estimated glomerular filtration rate; IQR, interquartile range.
aFinal model adjusted for age, sex, and comorbidities (diabetes mellitus, hypertension, proteinuria, and heart failure).
bComposite outcome=decline in eGFR 44ml/min per 1.73m2 per year or initiation of chronic renal replacement therapy.
cFinal model adjusted for age, sex, baseline eGFR, proteinuria, comorbidities (diabetes mellitus, hypertension, heart failure, cerebrovascular disease, peripheral vascular
disease, chronic pulmonary disease, liver disease, malignancy, and current smoking).
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follow-up, suggesting that the clinical decisions that lead to
the measurement of serum creatinine do not explain our
findings. Third, patients who develop AKI may be susceptible
to other processes that lead to progressive kidney disease
following angiography such as atheroemboli.24 Alternatively,
the long-term decline in eGFR following AKI may be due to
persisting renal damage after an episode of acute tubular
injury. Animal studies suggest that chronic changes to the
renal microvasculature may result from acute ischemic renal
injury.25,26 Our observations that kidney function was less
likely to recover to pre-angiography levels, and further
declined at a faster rate following an episode of AKI, are in
keeping with this hypothesis.
There are limitations to our study resulting from its
observational nature and the use of serum creatinine and
eGFR to determine kidney function. First, because this study
was conducted retrospectively, participant selection was
limited to patients who had pre- and post-angiography
serum creatinine measurements including measurements
within 7 days of coronary angiography as part of their
clinical care. Although many outpatients were thus excluded
because of the inability to ascertain AKI, these patients had
few risk factors for AKI and showed a low rate of CKD
progression during follow-up (decline in eGFR 0.1 ml/min
per 1.73 m2 per year). Therefore exclusion of these patients
from the study and restriction of the control group to those
with creatinine measurements are unlikely to have impacted
our findings. Second, episodes of AKI and their severity may
have been misclassified due to our dependence on existing
creatinine measurements captured following coronary angio-
graphy. However, our approach to identification of AKI is
most vulnerable to missing episodes of mild AKI or
underestimating the severity of AKI in those who developed
it. If such misclassification occurred, we anticipate this would
have underestimated the risk of renal outcomes following
moderate or severe AKI. Finally, measurement of long-term
study outcomes required that patients survive beyond
3 months to obtain repeated measures of kidney function.
Loss of patients due to death, ESRD, or loss to clinical follow-
up may thus have influenced results. However, because
patients with more rapid decline in kidney function are more
likely to experience death or ESRD,27,28 our estimates of the
rate of progression are likely conservative.29
The associations between AKI and progressive kidney
dysfunction have potentially important implications for
clinical management of patients following coronary angio-
graphy, given the availability of strategies that may slow the
progression of CKD.30,31 Our findings suggest a need for
clinical follow-up and further research evaluating strategies
to reduce progression of kidney disease in patients develop-
ing AKI following angiographic procedures.
In conclusion, patients with AKI are at increased risk of
sustaining a loss of kidney function following coronary
angiography, and further decline in kidney function during
long-term follow-up. Patients who develop AKI following
coronary angiography should be considered at increased risk
for progressive kidney disease and its associated complica-
tions. Further research should focus on the effects of
interventions to slow the progression of CKD in survivors
of radiocontrast-associated AKI.
MATERIALS AND METHODS
Study population
The study cohort was derived from the Alberta Provincial Project
for Outcome Assessment in Coronary Heart Disease (APPROACH),
a prospective data collection initiative that captures detailed
clinical information on all patients undergoing coronary angio-
graphy in Alberta, Canada at the time of their procedure.32
Coronary angiography was performed using nonionic iodinated
radiocontrast agents with the choice of low- or iso-osmolar
radiocontrast agents and use of N-acetylcysteine and intravenous
fluid made at the discretion of treating physicians.
The cohort consisted of all Alberta residents, X18 years of age,
undergoing coronary angiography from 1 January 2004 to 31
December 2006 in Alberta. To be eligible for inclusion, participants
required at least one serum creatinine measurement obtained from
an outpatient laboratory in each of two time periods relative to the
coronary angiogram: within a 6-month period preceding the
coronary angiogram; and 43 months following the angiogram
(Supplementary Figure S1). Patients with a renal transplant or who
were receiving dialysis before coronary angiography were excluded
based on linkage with the Northern and Southern Alberta Renal
Program registries33 or by physician billing claims (Canadian
Classification of Procedures codes 13.99A, 13.99B, 13.99C, 13.99D,
and 13.99O).34 Patients undergoing coronary artery bypass surgery
within 7 days of coronary angiography were excluded to minimize
causes of AKI other than those related to angiography. The cohort
entry date for each patient was the date of the first coronary
angiogram performed during the study period.
Measurement of exposure
All serum creatinine measurements performed in Alberta outpatient
facilities, or inpatient facilities that perform coronary angiography,
were obtained from the Alberta Kidney Disease Network repository
of laboratory data.35 AKI was defined based on the change in serum
creatinine concentration from the last pre-angiogram level to the
peak level observed within 7 days following the coronary angiogram.
We defined mild AKI as an increase in serum creatinine of 50–99%
or by X0.3 mg/dl, and moderate or severe AKI as an increase in
serum creatinine X100%.36 Patients with no creatinine measure-
ments within 7 days after angiography with which to ascertain AKI
were excluded.
Measurement of kidney function
The four-variable Modification of Diet in Renal Disease Study
equation37 was used to estimate eGFR before coronary angiography
and after 3 months following angiography (Supplementary
Figure S1). Although data on race were not available, misclassifica-
tion of eGFR was expected to be minimal as o1% of the Alberta
population is black.35 During the study period several Alberta
laboratories switched from nonstandardized creatinine assays to
isotope dilution mass spectroscopy-calibrated serum creatinine
assays;38 we used the non-isotope dilution mass spectroscopy
traceable Modification of Diet in Renal Disease study equation as
well as the isotope dilution mass spectroscopy-traceable Modification
of Diet in Renal Disease study equation to determine eGFR as
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appropriate based on the laboratory and date of creatinine
measurement.39 To reduce interlaboratory variation in eGFR, we
standardized creatinine measurements across provincial laboratories
to an isotope dilution mass spectroscopy reference standard,
and a laboratory-specific correction factor was applied as previously
described.35
Measurement of covariates
Age, sex, comorbidities, and information on coronary revascular-
ization procedures (percutaneous coronary intervention and
coronary artery bypass surgery) were determined from the
APPROACH database. Pre-angiography eGFR was estimated using
the last available outpatient creatinine measurements performed
within 6 months before coronary angiography. Post-angiography
eGFR was calculated using the first available outpatient creatinine
measurement performed 43 months after angiography. Provincial
laboratory data were used to obtain all outpatient urine protein
results collected before angiography.35 Urine protein was categorized
as absent, microalbuminuria, or macroalbuminuria/proteinuria as
previously described.40 Classification was based on the most recent
pre-angiography urine specimen for patients with two measure-
ments, and based on the median result when X3 measurements
were available.
Measurement of outcomes
Participants were followed until death (identified from Alberta
Vital Statistics Registry), the date of registration for chronic
dialysis or renal transplantation (identified from the Northern or
Southern Alberta Renal Program databases), or the study end date
(31 December 2007). We considered a sustained loss of kidney
function to be present after coronary angiography when the lowest
serum creatinine concentration obtained between 7 days and 3
months after angiography was more than 50% or 0.3 mg/dl greater
than the last pre-angiography measurement41,42 The subsequent
decline in kidney function occurring beyond 3 months following
angiography was assessed for patients with a post-angiography
eGFR o90 ml/min per 1.73 m2 (captured 43 months following
the angiogram) and was based upon the annual rate of decline in
eGFR during the remaining follow-up period.43 To address the effect
that AKI may have on acceleration of progression of kidney
function, we compared the rate of decline in eGFR in periods before
and after coronary angiography in the subgroup of these patients
who also had eGFR measurements that spanned a minimum of
1 year during the pre-angiography time period.16 Rapid progression
of kidney disease, defined as a rate of decline in eGFR 44 ml/min
per 1.73 m2 per year (ref. 28) or the initiation or chronic renal
replacement therapy (dialysis or renal transplant) during the follow-
up period beyond 3 months after coronary angiography, was also
identified.
Statistical analysis
Differences in baseline characteristics according to AKI status were
compared using analysis of variance or w2-tests as appropriate.
Logistic regression models including terms for covariates in Table 1
were fit to determine the association between AKI and decline in
kidney function at 3 months. For patients with post-angiography
eGFR o90 ml/min per 1.73 m2, further progression of kidney
dysfunction according to the annual rate of decline in eGFR in
ml/min per 1.73 m2 was determined using mixed-effect models with
random intercepts and random slopes. These models estimate the
rate of change in eGFR as a linear function over time, taking into
account the varying number and spacing of measurements of eGFR
as well as the variable follow-up for each subject, and avoid high
variability in estimates for patients with short follow-up.44,45 All
outpatient eGFR measurements obtained more than 3 months after
coronary angiography until death, initiation of renal replacement
therapy, or the study end-date were included in these models that
were adjusted for age, sex, proteinuria, and comorbidities. In a
subgroup analysis, the mixed-effect model was expanded to include
pre-angiography estimates of eGFR, incorporating a fixed effect to
assess differences in the annual rate of change in eGFR in the pre-
and post-angiography time periods. Logistic regression models were
used to determine the association between AKI and the risk of rapid
progression occurring 43 months after angiography in patients
with post-angiography eGFR o90 ml/min per 1.73 m2. Stepwise
elimination and backward selection were used to select variables for
inclusion in the final logistic regression and mixed-effect models.
The normal distribution of random effects for the mixed-effect
model and linearity of the logit for logistic regression models were
tested using graphical approaches. All statistical analyses were
conducted using STATA (version 10.0; STATA Corp., College
Station, TX). The conjoint health research ethics board of the
University of Calgary approved the study.
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